Institut Jules Bordet
Anderlecht, Belgium
68 recruiting
Showing 1–20 of 85 trials
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled384 locationsNCT07062965
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled288 locationsNCT06578247
Recruiting
Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled295 locationsNCT07028853
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled536 locationsNCT06492616
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled286 locationsNCT06252649
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled145 locationsNCT06973187
Recruiting
Phase 1Phase 2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled66 locationsNCT05768139
Recruiting
Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Leiomyosarcoma
PharmaMar450 enrolled97 locationsNCT06088290
Recruiting
Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 2
Study of Lacutamab in Peripheral T-cell Lymphoma
Relapse/RecurrencePeripheral T Cell Lymphoma
The Lymphoma Academic Research Organisation56 enrolled64 locationsNCT04984837
Recruiting
Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Colorectal Cancer Stage IIIColorectal Cancer Stage II
BioNTech SE327 enrolled121 locationsNCT04486378
Recruiting
Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Small Cell Lung CancerLimited Stage Small Cell Lung Cancer
Amgen400 enrolled204 locationsNCT06117774
Recruiting
Phase 3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled169 locationsNCT06149286
Recruiting
Phase 1Phase 2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595